Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares reached a new 52-week low during trading on Monday . The ...
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus recommendation of “Buy” by the ...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...
H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on ORKA stock, giving a Buy rating yesterday.Pick the best stocks ...
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at $41.00. Pick the best stocks and maximize your ...
The stock jumped in April 2024 after Arca announced a merger with Oruka Therapeutics, a private, clinical-stage biotech company focused on treating chronic skin diseases, including plaque psoriasis.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback